RYSTIGGO (rozanolixizumab-noli) is a targeted treatment for generalized myasthenia gravis (gMG). In gMG, harmful anti-AChR or anti-MuSK antibodies can get in the way of signals between nerves and certain receptors on muscles. In the neuromuscular junction, where nerves and muscles meet, this loss of signaling can lead to muscle weakness, fatigue, shortness of breath, and other gMG symptoms. These harmful antibodies can continue to stay in your system because of an immune system protein called FcRn (neonatal Fc receptor). FcRn can extend the life of certain antibodies, including anti-AChR and anti-MuSK antibodies, by preventing them from being broken down by your cells’ natural waste clearance system. RYSTIGGO works by specifically targeting FcRn and blocking it from extending the life of these harmful antibodies. This helps ensure they are broken down in the cell normally.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.